ARS Pharmaceuticals (SPRY) Competitors $13.97 +0.05 (+0.36%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SPRY vs. TLX, BPMC, SRPT, NUVL, AXSM, VRNA, GRFS, KRYS, ADMA, and CYTKShould you be buying ARS Pharmaceuticals stock or one of its competitors? The main competitors of ARS Pharmaceuticals include Telix Pharmaceuticals Limited American Depositary Shares (TLX), Blueprint Medicines (BPMC), Sarepta Therapeutics (SRPT), Nuvalent (NUVL), Axsome Therapeutics (AXSM), Verona Pharma (VRNA), Grifols (GRFS), Krystal Biotech (KRYS), ADMA Biologics (ADMA), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical products" industry. ARS Pharmaceuticals vs. Telix Pharmaceuticals Limited American Depositary Shares Blueprint Medicines Sarepta Therapeutics Nuvalent Axsome Therapeutics Verona Pharma Grifols Krystal Biotech ADMA Biologics Cytokinetics ARS Pharmaceuticals (NASDAQ:SPRY) and Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, community ranking, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability. Is SPRY or TLX more profitable? Telix Pharmaceuticals Limited American Depositary Shares' return on equity of 0.00% beat ARS Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ARS PharmaceuticalsN/A -22.56% -21.82% Telix Pharmaceuticals Limited American Depositary Shares N/A N/A N/A Do institutionals and insiders hold more shares of SPRY or TLX? 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 40.1% of ARS Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community believe in SPRY or TLX? ARS Pharmaceuticals received 21 more outperform votes than Telix Pharmaceuticals Limited American Depositary Shares when rated by MarketBeat users. However, 100.00% of users gave Telix Pharmaceuticals Limited American Depositary Shares an outperform vote while only 86.21% of users gave ARS Pharmaceuticals an outperform vote. CompanyUnderperformOutperformARS PharmaceuticalsOutperform Votes2586.21% Underperform Votes413.79%Telix Pharmaceuticals Limited American Depositary SharesOutperform Votes4100.00% Underperform VotesNo Votes Do analysts prefer SPRY or TLX? ARS Pharmaceuticals presently has a consensus target price of $31.00, suggesting a potential upside of 124.30%. Telix Pharmaceuticals Limited American Depositary Shares has a consensus target price of $22.00, suggesting a potential upside of 27.79%. Given ARS Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe ARS Pharmaceuticals is more favorable than Telix Pharmaceuticals Limited American Depositary Shares.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ARS Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Telix Pharmaceuticals Limited American Depositary Shares 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable earnings & valuation, SPRY or TLX? Telix Pharmaceuticals Limited American Depositary Shares has higher revenue and earnings than ARS Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioARS Pharmaceuticals$89.15M15.21-$54.37M$0.08172.76Telix Pharmaceuticals Limited American Depositary Shares$783.21M7.43N/AN/AN/A Does the media favor SPRY or TLX? In the previous week, ARS Pharmaceuticals and ARS Pharmaceuticals both had 5 articles in the media. ARS Pharmaceuticals' average media sentiment score of 1.30 beat Telix Pharmaceuticals Limited American Depositary Shares' score of 0.25 indicating that ARS Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ARS Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Telix Pharmaceuticals Limited American Depositary Shares 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryARS Pharmaceuticals beats Telix Pharmaceuticals Limited American Depositary Shares on 9 of the 13 factors compared between the two stocks. Get ARS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRY vs. The Competition Export to ExcelMetricARS PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.35B$6.80B$5.51B$7.66BDividend YieldN/A3.09%5.11%4.22%P/E Ratio-27.077.2922.3418.23Price / Sales15.21237.82391.77101.43Price / CashN/A65.8538.1834.62Price / Book5.766.366.734.16Net Income-$54.37M$142.94M$3.22B$248.05M7 Day Performance-3.89%1.60%1.64%1.62%1 Month Performance10.66%-1.90%-1.51%0.15%1 Year Performance58.86%0.83%16.82%4.01% ARS Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPRYARS Pharmaceuticals3.1181 of 5 stars$13.97+0.4%$31.00+121.9%+61.9%$1.37B$89.15M-27.3990News CoveragePositive NewsTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.37-2.0%$22.00+34.4%N/A$5.53B$783.21M0.00N/AAnalyst RevisionNews CoverageBPMCBlueprint Medicines2.5549 of 5 stars$83.73-1.1%$124.95+49.2%-5.0%$5.35B$508.82M-77.53640Upcoming EarningsAnalyst ForecastPositive NewsSRPTSarepta Therapeutics4.7339 of 5 stars$55.05+2.3%$158.70+188.3%-52.8%$5.34B$1.90B44.04840News CoveragePositive NewsNUVLNuvalent1.8954 of 5 stars$70.57-1.5%$115.50+63.7%+11.7%$5.05BN/A-20.3440News CoveragePositive NewsAXSMAxsome Therapeutics4.8294 of 5 stars$103.30-1.1%$169.80+64.4%+49.2%$5.04B$385.69M-17.25380Upcoming EarningsAnalyst ForecastShort Interest ↓Positive NewsVRNAVerona Pharma2.9036 of 5 stars$60.37+2.5%$75.43+24.9%+370.5%$4.88B$42.28M-31.4430Earnings ReportAnalyst ForecastShort Interest ↓News CoveragePositive NewsGRFSGrifols3.8747 of 5 stars$6.98-1.4%N/A+9.3%$4.80B$7.21B5.9726,300Short Interest ↓Positive NewsKRYSKrystal Biotech4.903 of 5 stars$161.83-4.0%$220.00+35.9%+8.0%$4.68B$290.52M54.12210Upcoming EarningsAnalyst ForecastNews CoveragePositive NewsADMAADMA Biologics1.487 of 5 stars$19.24-9.7%$22.50+16.9%+266.4%$4.55B$426.45M68.71530News CoveragePositive NewsGap DownCYTKCytokinetics4.2589 of 5 stars$37.74-4.4%$81.63+116.3%-34.0%$4.50B$18.47M-7.01250Upcoming EarningsInsider Trade Related Companies and Tools Related Companies TLX Competitors BPMC Competitors SRPT Competitors NUVL Competitors AXSM Competitors VRNA Competitors GRFS Competitors KRYS Competitors ADMA Competitors CYTK Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SPRY) was last updated on 4/30/2025 by MarketBeat.com Staff From Our Partners"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredChina’s next move could destroy U.S. techThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ARS Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SPRY Stock Free SPRY Stock Alerts